Biomarker Diagnostics - The Enhanced Velocity Electrophoretic ImmunoAssay (EVEIA HIA) is unique in the industry as it is a completely solution-phase immunoassay. Unlike widely used conventional Enzyme-Linked Immunosorbent Assays (ELISAs) which rely on surface interactions for target capture and signal generation, no binding to solid surfaces such as beads or wells is required for the EVEIA system. This leads to faster assay times, inherently reduced background, and in many cases, results in a sensitivity and specificity advantage over ELISA techniques, which is of great significance for many targets. There are currently two patents pending around the technology. The system takes advantage of the speed of solution phase binding while eliminating negative effects of non-specific binding to surfaces that frequently limit sensitivity.  In addition, by being able to utilize a large excess of antibody relative to the target, sensitivity is dramatically increased.

The EVEIA Technology uses 3 Basic Principles:

1. Formation of Capturable and Detectable Immune Complexes
2. Capture of the Specific Complexes via Avidin-Biotin Linkages with Electrophoretically Immobile Soluble Polymer
3. Separation of Captured Specific Immune Complexes from All Other Sample Proteins and Labeled Antibodies via Solution Electrophoresis

Camera View of Assay Process:

Images Represent Actual Movement of Fluorescently Tagged Antibody

Eveia’s technology has been reduced to practice using the prototype optical system shown above. This system is in use to develop assays while the engineering group continues to develop the optical system.